New hope for Hard-to-Treat colorectal cancer: liquid biopsy guides smarter drug choice
NCT ID NCT04776655
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study looks at people with advanced colorectal cancer whose tumor tissue shows no RAS/BRAF mutation, but a liquid biopsy (blood test) finds a RAS mutation. It compares two standard drug combos (FOLFIRI plus either cetuximab or bevacizumab) to see which works better at stopping the cancer from growing. About 280 adults will take part, and the goal is to find the best first treatment for this specific group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AUSL/IRCCS di Reggio Emilia
Reggio Emilia, Reggio Emilia, 42123, Italy
-
Azienda ULSS 3 Serenissima
Mirano, VE, 30035, Italy
-
Ospedale Civile di Guastalla
Guastalla, Reggio Emilia, 42016, Italy
-
Ospedale San Salvatore
Coppito, L'Aquila, 67100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?